He Jiankui plans gene editing for Alzheimer’s after prison term

Chinese scientist He Jiankui, who served time in prison for creating the world’s first gene-edited babies, now intends to pursue similar work to combat Alzheimer’s disease. He has criticized Silicon Valley’s efforts in the field as a “Nazi eugenic experiment.” This development revives ethical debates in biotechnology.

In 2018, He Jiankui made headlines by announcing at a scientific conference in Hong Kong that he had produced the world’s first gene-edited babies. The soft-spoken researcher confirmed the reports amid a tense atmosphere in the packed auditorium, adjusting his microphone before addressing the audience.

His actions led to his imprisonment in China for violating regulations on gene editing. Now, years later, He Jiankui is preparing to resume such experiments, this time targeting Alzheimer’s disease with the goal of eradicating it.

He has voiced strong objections to ongoing projects in Silicon Valley, labeling them a “Nazi eugenic experiment.” This perspective underscores the ongoing ethical tensions surrounding gene-editing technologies like CRISPR, which He pioneered in his controversial work.

The announcement, detailed in a recent Wired article, highlights the persistent global divide on the boundaries of genetic intervention. While He’s past work sparked international condemnation for ethical lapses, his renewed ambitions signal a bold push forward in medical applications, though under heightened scrutiny.

Articoli correlati

Scientists at Virginia Tech using CRISPR tools to improve memory in aged rats, illustrating potential for combating cognitive decline.
Immagine generata dall'IA

Virginia Tech team improves memory in aged rats with targeted gene-editing

Riportato dall'IA Immagine generata dall'IA Verificato

Scientists at Virginia Tech report that tuning specific molecular pathways with CRISPR-based tools improved memory in older rats across two peer‑reviewed studies, pointing to possible routes for tackling age‑related cognitive decline.

Lo specialista in economia della salute Martin Morgenstern ha dichiarato in un'intervista che l'editing genetico trasformerà i trattamenti medici nelle prossime decadi. Secondo lui, tecnologie come CRISPR permetteranno di alterare geni specifici per combattere condizioni come il colesterolo alto. Questo approccio promette di essere più preciso dei farmaci tradizionali, sebbene comporti rischi intrinseci.

Riportato dall'IA

At October's Pandemic Research Alliance Symposium, researcher Wei Zhao presented an innovative concept using CRISPR to combat influenza. The idea targets the virus's replication process, potentially halting its spread. This development highlights ongoing efforts in gene-editing research against relentless flu strains.

A new genetic study has identified 331 genes essential for transforming stem cells into brain cells, including a novel gene linked to neurodevelopmental disorders. Led by scientists at the Hebrew University of Jerusalem, the research highlights how early genetic disruptions can lead to conditions like autism and developmental delay. The findings, published in Nature Neuroscience, also reveal patterns in how these disorders are inherited.

Riportato dall'IA Verificato

Researchers have developed a genomic mapping technique that reveals how thousands of genes work together to influence disease risk, helping to bridge gaps left by traditional genetic studies. The approach, described in a Nature paper led by Gladstone Institutes and Stanford University scientists, combines large-scale cell experiments with population genetics data to highlight promising targets for future therapies and deepen understanding of conditions such as blood disorders and immune-mediated diseases.

Researchers have demonstrated that restoring levels of a key brain energy molecule can reverse advanced Alzheimer's disease in mouse models, repairing damage and restoring cognitive function. The study, published on December 22, challenges the long-held view that the condition is irreversible. Findings from human brain tissue support the approach's potential relevance to patients.

Riportato dall'IA

Chinese semiconductor engineer Xu Zhenpeng says he left the United States for China to pursue a more independent research environment and long-term academic goals. China's rapidly evolving advanced manufacturing research ecosystem was a key driver.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta